Why the study?
Shengmai injection has been used to treat heart failure, but the molecular mechanisms of its protection against doxorubicin-induced cardiotoxicity remained to be determined.
Does shengmai injection reduce doxorubicin-induced cardiotoxicity in preclinical models?
Population
In vivo doxorubicin-induced cardiotoxicity model and in vitro H9c2 cells
Comparison
Shengmai injection vs dexrazoxane, doxorubicin alone, or controls
Design
In vivo and in vitro laboratory experimental study
Authors
Loading...
Animal data support SMI exploration in doxorubicin models; human trials needed before any clinical consideration.
Does shengmai injection reduce doxorubicin-induced cardiotoxicity in preclinical models?
Shengmai injection protects against doxorubicin-induced cardiotoxicity in preclinical models via activation of the Nrf2/Keap1 signaling pathway.
Zhou et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: